Miracle Endometriosis Treatment Developed in Lyon?

A medical breakthrough in Lyon, France, is offering new hope to millions of women suffering from severe endometriosis. High-Intensity Focused Ultrasound (HIFU), a non-invasive technology, has emerged as a viable alternative to traditional, invasive surgery, marking a significant shift in the management of this debilitating condition.

A Non-Invasive Alternative to Major Surgery

For women with severe forms of endometriosis, treatment has historically required long and sometimes mutilating surgical procedures that can last several hours and lead to significant complications. The introduction of HIFU technology changes this trajectory by providing a mini-invasive option that requires no incisions and leaves no scars.

Developed at the Hospices Civils de Lyon (HCL), the technique uses precisely focused ultrasound waves to target and destroy diseased tissues within a matter of minutes. This approach allows patients to be treated on an outpatient basis or through a short hospital stay, enabling them to return home the same day. According to experts, the treatment results in a rapid reduction of pain without negatively impacting fertility.

From Prostate Cancer Treatment to Endometriosis Care

The technology was not originally designed for gynecological health; it was initially developed to treat prostate cancer. Professor Gil Dubernard, head of the gynecology-obstetrics department at the Hôpital de la Croix-Rousse, became the first in the world to adapt HIFU for the treatment of endometriosis lesions, specifically those affecting the rectum.

This adaptation was made possible through a collaboration between the Hospices Civils de Lyon, INSERM, and the company EDAP-TMS. By April 2026, the procedure has transitioned from an experimental phase to a regular therapeutic standard in Lyon.

Clinical Validation and European Recognition

The path to clinical implementation was supported by extensive research. Between 2015 and 2024, a study involving more than 140 patients across nine different French centers produced highly encouraging results. These findings paved the way for the treatment to receive its CE marking in March 2025, a critical milestone for its recognition and adoption across Europe.

The timing of this advancement is particularly poignant, as March 28, 2026, marked World Endometriosis Day. The disease, which affects one in ten women of childbearing age, remains the leading cause of infertility in France. The ability to treat severe lesions without the risks of heavy surgery represents a major advancement in public health and women’s wellness.

Further details on this development can be found in the original report: Endométriose : un traitement miraculeux conçu à Lyon ?